speb/financial-data huggingface dataset:
NUG.V income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -48109.00
NUG.V income_statement (quarterly, 2025-12-31) — Normalized Income: -48317.00
NUG.V cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -10078.00
NUG.V income_statement (quarterly, 2025-12-31) — Operating Income: -48364.00
NUG.V income_statement (quarterly, 2025-12-31) — Operating Revenue: 0.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 2895096.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Other Equity Interest: 24835498.00
NUG.V income_statement (quarterly, 2025-12-31) — Other Gand A: 871.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Other Non Current Assets: 638568.00
NUG.V income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 47237.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Other Short Term Investments: 4421.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Payables: 565652.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 565652.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 30429.00
NUG.V income_statement (quarterly, 2025-12-31) — Pretax Income: -48317.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Receivables: 8409.00
NUG.V income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 256.00
NUG.V income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 255.00
NUG.V income_statement (quarterly, 2025-12-31) — Rent And Landing Fees: 0.00
NUG.V income_statement (quarterly, 2025-12-31) — Rent Expense Supplemental: 0.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -81136195.00
NUG.V income_statement (quarterly, 2025-12-31) — Salaries And Wages: 0.00
NUG.V cash_flow (quarterly, 2025-12-31) — Sale Of PPE: 0.00
NUG.V income_statement (quarterly, 2025-12-31) — Selling General And Administration: 871.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Share Issued: 2895096.00
NUG.V income_statement (quarterly, 2025-12-31) — Special Income Charges: 0.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 143966.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 143966.00
NUG.V income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
NUG.V income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Total Assets: 709618.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 143966.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 143966.00
NUG.V income_statement (quarterly, 2025-12-31) — Total Expenses: 48364.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 565652.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 638824.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 0.00
NUG.V income_statement (quarterly, 2025-12-31) — Total Unusual Items: 0.00
NUG.V income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: 0.00
NUG.V balance_sheet (quarterly, 2025-12-31) — Working Capital: -494853.00
NUG.V income_statement (annual, 2026-03-31) — +Operating Expense: 301850.00
NUG.V income_statement (quarterly, 2026-03-31) — +Operating Expense: 114990.00
NUG.V income_statement (annual, 2026-03-31) — +Total Revenue: 0.00
NUG.V income_statement (quarterly, 2026-03-31) — +Total Revenue: 0.00
NUG.V balance_sheet (annual, 2026-03-31) — Accounts Payable: 58446.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 58446.00
NUG.V balance_sheet (annual, 2026-03-31) — Accounts Receivable: 11571.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 11571.00
NUG.V balance_sheet (annual, 2026-03-31) — Accumulated Depreciation: -361002.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -361002.00
NUG.V cash_flow (annual, 2026-03-31) — Asset Impairment Charge: 0.00
NUG.V cash_flow (quarterly, 2026-03-31) — Asset Impairment Charge: 0.00
NUG.V cash_flow (annual, 2026-03-31) — Beginning Cash Position: 105969.00
NUG.V cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 27540.00
NUG.V balance_sheet (annual, 2026-03-31) — Capital Stock: 59740401.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Capital Stock: 59740401.00
NUG.V balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 17704.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 17704.00
NUG.V balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 17704.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 17704.00
NUG.V balance_sheet (annual, 2026-03-31) — Cash Financial: 17704.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Cash Financial: 17704.00
NUG.V cash_flow (annual, 2026-03-31) — Cash Flow From Continuing Financing Activities: 0.00
NUG.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 0.00
NUG.V cash_flow (annual, 2026-03-31) — Cash Flow From Continuing Investing Activities: 0.00
NUG.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -8283.00
NUG.V cash_flow (annual, 2026-03-31) — Cash Flow From Continuing Operating Activities: -88265.00
NUG.V cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -1553.00
NUG.V cash_flow (annual, 2026-03-31) — Change In Payable: 191691.00
NUG.V cash_flow (quarterly, 2026-03-31) — Change In Payable: 79024.00
NUG.V cash_flow (annual, 2026-03-31) — Change In Payables And Accrued Expense: 191691.00
NUG.V cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: 79024.00
NUG.V cash_flow (annual, 2026-03-31) — Change In Prepaid Assets: 17443.00
NUG.V cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: 29443.00
NUG.V cash_flow (annual, 2026-03-31) — Change In Receivables: -3947.00
NUG.V cash_flow (quarterly, 2026-03-31) — Change In Receivables: -3162.00
NUG.V cash_flow (annual, 2026-03-31) — Change In Working Capital: 205187.00
NUG.V cash_flow (quarterly, 2026-03-31) — Change In Working Capital: 105305.00
NUG.V cash_flow (annual, 2026-03-31) — Changes In Cash: -88265.00
NUG.V cash_flow (quarterly, 2026-03-31) — Changes In Cash: -9836.00
NUG.V balance_sheet (annual, 2026-03-31) — Common Stock: 59740401.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Common Stock: 59740401.00
NUG.V balance_sheet (annual, 2026-03-31) — Common Stock Equity: 4525.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 4525.00
NUG.V cash_flow (annual, 2026-03-31) — Common Stock Issuance: 0.00
NUG.V cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 0.00
NUG.V income_statement (annual, 2026-03-31) — Cost Of Revenue: 1022.00
NUG.V income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 255.00
NUG.V balance_sheet (annual, 2026-03-31) — Current Assets: 30261.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Current Assets: 30261.00
NUG.V balance_sheet (annual, 2026-03-31) — Current Liabilities: 637919.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 637919.00
NUG.V cash_flow (annual, 2026-03-31) — Depreciation: 1022.00
NUG.V cash_flow (quarterly, 2026-03-31) — Depreciation: 256.00
NUG.V cash_flow (annual, 2026-03-31) — Depreciation Amortization Depletion: 1022.00
NUG.V cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 256.00
NUG.V cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 1022.00
NUG.V cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 256.00
NUG.V income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: -322380.00
NUG.V income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -135020.00
NUG.V balance_sheet (annual, 2026-03-31) — Dueto Related Parties Current: 579473.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Dueto Related Parties Current: 579473.00
NUG.V income_statement (annual, 2026-03-31) — EBIT: -302872.00
NUG.V income_statement (quarterly, 2026-03-31) — EBIT: -115245.00
NUG.V income_statement (annual, 2026-03-31) — EBITDA: -301850.00
NUG.V income_statement (quarterly, 2026-03-31) — EBITDA: -114989.00
NUG.V cash_flow (annual, 2026-03-31) — Effect Of Exchange Rate Changes: 0.00
NUG.V cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: 0.00
NUG.V cash_flow (annual, 2026-03-31) — End Cash Position: 17704.00
NUG.V cash_flow (quarterly, 2026-03-31) — End Cash Position: 17704.00
NUG.V cash_flow (annual, 2026-03-31) — Financing Cash Flow: 0.00
NUG.V cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 0.00
NUG.V balance_sheet (annual, 2026-03-31) — Fixed Assets Revaluation Reserve: -3300159.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Fixed Assets Revaluation Reserve: -3300159.00
NUG.V cash_flow (annual, 2026-03-31) — Free Cash Flow: -88265.00
NUG.V cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -1553.00
NUG.V cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -6757.00
NUG.V income_statement (annual, 2026-03-31) — Gain On Sale Of Ppe: 0.00
NUG.V income_statement (quarterly, 2026-03-31) — Gain On Sale Of Ppe: 0.00
NUG.V income_statement (annual, 2026-03-31) — Gain On Sale Of Security: -26531.00
NUG.V income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: -26530.00
NUG.V balance_sheet (annual, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: -3300159.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: -3300159.00
NUG.V income_statement (annual, 2026-03-31) — General And Administrative Expense: 267196.00
NUG.V income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 221882.00
NUG.V balance_sheet (annual, 2026-03-31) — Gross PPE: 361002.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Gross PPE: 361002.00
NUG.V income_statement (annual, 2026-03-31) — Gross Profit: -1022.00
NUG.V income_statement (quarterly, 2026-03-31) — Gross Profit: -255.00
NUG.V income_statement (annual, 2026-03-31) — Impairment Of Capital Assets: 0.00
NUG.V income_statement (quarterly, 2026-03-31) — Impairment Of Capital Assets: 0.00
NUG.V income_statement (annual, 2026-03-31) — Insurance And Claims: 11900.00
NUG.V income_statement (quarterly, 2026-03-31) — Insurance And Claims: 11800.00
NUG.V income_statement (annual, 2026-03-31) — Interest Income: 266.00
NUG.V income_statement (quarterly, 2026-03-31) — Interest Income: -2.00
NUG.V income_statement (annual, 2026-03-31) — Interest Income Non Operating: 266.00
NUG.V income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: -2.00
NUG.V balance_sheet (annual, 2026-03-31) — Invested Capital: 4525.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Invested Capital: 4525.00
NUG.V cash_flow (annual, 2026-03-31) — Investing Cash Flow: 0.00
NUG.V cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -8283.00
NUG.V cash_flow (annual, 2026-03-31) — Issuance Of Capital Stock: 0.00
NUG.V cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 0.00
NUG.V balance_sheet (annual, 2026-03-31) — Leases: 29509.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Leases: 29509.00
NUG.V balance_sheet (annual, 2026-03-31) — Machinery Furniture Equipment: 331493.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 331493.00
NUG.V cash_flow (annual, 2026-03-31) — Net Common Stock Issuance: 0.00
NUG.V cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: 0.00
NUG.V cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: 34663.00
NUG.V income_statement (annual, 2026-03-31) — Net Income: -322380.00
NUG.V income_statement (quarterly, 2026-03-31) — Net Income: -135020.00
NUG.V income_statement (annual, 2026-03-31) — Net Income Common Stockholders: -322380.00
NUG.V income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -135020.00
NUG.V income_statement (annual, 2026-03-31) — Net Income Continuous Operations: -322380.00
NUG.V income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -135020.00
NUG.V income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -322380.00
NUG.V income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -135020.00
NUG.V income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -322380.00
NUG.V income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -135020.00
NUG.V cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: -322380.00
NUG.V cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -135020.00
NUG.V income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: -322380.00
NUG.V income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -135020.00
NUG.V income_statement (annual, 2026-03-31) — Net Interest Income: 266.00
NUG.V income_statement (quarterly, 2026-03-31) — Net Interest Income: -2.00
NUG.V income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: 266.00
NUG.V income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -2.00
NUG.V balance_sheet (annual, 2026-03-31) — Net PPE: 0.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Net PPE: 0.00
NUG.V cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: 0.00
NUG.V cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: 0.00
NUG.V balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 4525.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 4525.00
NUG.V income_statement (annual, 2026-03-31) — Normalized EBITDA: -282076.00
NUG.V income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -95216.00
NUG.V income_statement (annual, 2026-03-31) — Normalized Income: -302606.00
NUG.V income_statement (quarterly, 2026-03-31) — Normalized Income: -115247.00
NUG.V cash_flow (annual, 2026-03-31) — Operating Cash Flow: -88265.00
NUG.V cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -1553.00
NUG.V cash_flow (annual, 2026-03-31) — Operating Gains Losses: 27906.00
NUG.V income_statement (annual, 2026-03-31) — Operating Income: -302872.00
NUG.V income_statement (quarterly, 2026-03-31) — Operating Income: -115245.00
NUG.V income_statement (annual, 2026-03-31) — Operating Revenue: 0.00
NUG.V income_statement (quarterly, 2026-03-31) — Operating Revenue: 0.00
NUG.V balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 2895096.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 2895096.00
NUG.V balance_sheet (annual, 2026-03-31) — Other Equity Interest: 24835498.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 24835498.00
NUG.V income_statement (annual, 2026-03-31) — Other Gand A: 253358.00
NUG.V income_statement (quarterly, 2026-03-31) — Other Gand A: 208839.00
NUG.V income_statement (annual, 2026-03-31) — Other Income Expense: -19774.00
NUG.V income_statement (quarterly, 2026-03-31) — Other Income Expense: -19773.00
NUG.V balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 612183.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 612183.00
NUG.V income_statement (annual, 2026-03-31) — Other Operating Expenses: 34654.00
NUG.V income_statement (quarterly, 2026-03-31) — Other Operating Expenses: -106892.00
NUG.V balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 0.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 0.00
NUG.V income_statement (annual, 2026-03-31) — Other Special Charges: -6757.00
NUG.V balance_sheet (annual, 2026-03-31) — Payables: 637919.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Payables: 637919.00
NUG.V balance_sheet (annual, 2026-03-31) — Payables And Accrued Expenses: 637919.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 637919.00
NUG.V balance_sheet (annual, 2026-03-31) — Prepaid Assets: 986.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 986.00
NUG.V income_statement (annual, 2026-03-31) — Pretax Income: -322380.00
NUG.V income_statement (quarterly, 2026-03-31) — Pretax Income: -135020.00
NUG.V balance_sheet (annual, 2026-03-31) — Receivables: 11571.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Receivables: 11571.00
NUG.V income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 1022.00
NUG.V income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 255.00
NUG.V income_statement (annual, 2026-03-31) — Reconciled Depreciation: 1022.00
NUG.V income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 256.00
NUG.V income_statement (annual, 2026-03-31) — Rent And Landing Fees: 1938.00
NUG.V income_statement (quarterly, 2026-03-31) — Rent And Landing Fees: 1243.00
NUG.V income_statement (annual, 2026-03-31) — Rent Expense Supplemental: 1938.00
NUG.V income_statement (quarterly, 2026-03-31) — Rent Expense Supplemental: 1243.00
NUG.V balance_sheet (annual, 2026-03-31) — Retained Earnings: -81271215.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -81271215.00
NUG.V income_statement (annual, 2026-03-31) — Salaries And Wages: 0.00
NUG.V income_statement (quarterly, 2026-03-31) — Salaries And Wages: 0.00
NUG.V cash_flow (annual, 2026-03-31) — Sale Of PPE: 0.00
NUG.V cash_flow (quarterly, 2026-03-31) — Sale Of PPE: 0.00
NUG.V income_statement (annual, 2026-03-31) — Selling General And Administration: 267196.00
NUG.V income_statement (quarterly, 2026-03-31) — Selling General And Administration: 221882.00
NUG.V balance_sheet (annual, 2026-03-31) — Share Issued: 2895096.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Share Issued: 2895096.00
NUG.V income_statement (annual, 2026-03-31) — Special Income Charges: 6757.00
NUG.V income_statement (quarterly, 2026-03-31) — Special Income Charges: 6757.00
NUG.V balance_sheet (annual, 2026-03-31) — Stockholders Equity: 4525.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 4525.00
NUG.V balance_sheet (annual, 2026-03-31) — Tangible Book Value: 4525.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 4525.00
NUG.V income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
NUG.V income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
NUG.V income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.00
NUG.V income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.00
NUG.V balance_sheet (annual, 2026-03-31) — Total Assets: 642444.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Total Assets: 642444.00
NUG.V balance_sheet (annual, 2026-03-31) — Total Capitalization: 4525.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 4525.00
NUG.V balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 4525.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 4525.00
NUG.V income_statement (annual, 2026-03-31) — Total Expenses: 302872.00
NUG.V income_statement (quarterly, 2026-03-31) — Total Expenses: 115245.00
NUG.V balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 637919.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 637919.00
NUG.V balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 612183.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 612183.00
NUG.V balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 0.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 0.00
NUG.V income_statement (annual, 2026-03-31) — Total Unusual Items: -19774.00
NUG.V income_statement (quarterly, 2026-03-31) — Total Unusual Items: -19773.00
NUG.V income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: -19774.00
NUG.V income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -19773.00
NUG.V balance_sheet (annual, 2026-03-31) — Working Capital: -607658.00
NUG.V balance_sheet (quarterly, 2026-03-31) — Working Capital: -607658.00
NURECA.NS income_statement (annual, 2022-03-31) — +Operating Expense: 681190000.00
NURECA.NS income_statement (annual, 2022-03-31) — +Total Revenue: 2555480000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Accounts Payable: 47210000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Accounts Receivable: 28940000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Accumulated Depreciation: -16030000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Additional Paid In Capital: 987790000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Allowance For Doubtful Accounts Receivable: 0.00
NURECA.NS income_statement (annual, 2022-03-31) — Amortization: 820000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Amortization Cash Flow: 820000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Available For Sale Securities: 22240000.00
NURECA.NS income_statement (annual, 2022-03-31) — Basic Average Shares: 10000175.00
NURECA.NS income_statement (annual, 2022-03-31) — Basic EPS: 44.96
NURECA.NS cash_flow (annual, 2022-03-31) — Beginning Cash Position: 172420000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Buildings And Improvements: 50390000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Capital Expenditure: -59990000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Capital Lease Obligations: 43290000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Capital Stock: 100000000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Cash And Cash Equivalents: 82490000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Cash Cash Equivalents And Short Term Investments: 927100000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Cash Dividends Paid: -49930000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Cash Equivalents: 80000000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Cash Financial: 2490000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Change In Inventory: -264010000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Change In Other Current Assets: -42710000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Change In Other Current Liabilities: -9040000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Change In Payable: -39590000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Change In Receivables: -26140000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Change In Working Capital: -378980000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Changes In Cash: -89920000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Common Stock: 100000000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Common Stock Equity: 2031990000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Common Stock Issuance: 0.00
NURECA.NS income_statement (annual, 2022-03-31) — Cost Of Revenue: 1326240000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Current Assets: 2061930000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Current Capital Lease Obligation: 10480000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Current Debt: 760000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Current Debt And Capital Lease Obligation: 11240000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Current Liabilities: 122380000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Current Provisions: 1690000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Depreciation: 14820000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Depreciation And Amortization: 14820000.00
NURECA.NS income_statement (annual, 2022-03-31) — Depreciation And Amortization In Income Statement: 14820000.00
NURECA.NS income_statement (annual, 2022-03-31) — Depreciation Income Statement: 14000000.00
NURECA.NS income_statement (annual, 2022-03-31) — Diluted Average Shares: 10000175.00
NURECA.NS income_statement (annual, 2022-03-31) — Diluted EPS: 44.96
NURECA.NS income_statement (annual, 2022-03-31) — Diluted NI Availto Com Stockholders: 449600000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Dividends Payable: 70000.00
NURECA.NS income_statement (annual, 2022-03-31) — EBIT: 614170000.00
NURECA.NS income_statement (annual, 2022-03-31) — EBITDA: 628990000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Effect Of Exchange Rate Changes: -10000.00
NURECA.NS cash_flow (annual, 2022-03-31) — End Cash Position: 82490000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Financing Cash Flow: -73020000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Finished Goods: 631770000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Free Cash Flow: -46000000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Gain Loss On Investment Securities: -6510000.00
NURECA.NS income_statement (annual, 2022-03-31) — General And Administrative Expense: 52160000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Goodwill And Other Intangible Assets: 28150000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Gross Accounts Receivable: 28940000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Gross PPE: 94000000.00
NURECA.NS income_statement (annual, 2022-03-31) — Gross Profit: 1229240000.00
NURECA.NS income_statement (annual, 2022-03-31) — Interest Expense: 4360000.00
NURECA.NS income_statement (annual, 2022-03-31) — Interest Expense Non Operating: 4360000.00
NURECA.NS income_statement (annual, 2022-03-31) — Interest Income: 52400000.00
NURECA.NS income_statement (annual, 2022-03-31) — Interest Income Non Operating: 52400000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Interest Paid Cff: -4340000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Interest Received Cfi: 40410000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Inventory: 631770000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Invested Capital: 2032750000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Investing Cash Flow: -30890000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Investmentin Financial Assets: 22240000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Issuance Of Capital Stock: 0.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Long Term Capital Lease Obligation: 32810000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Long Term Debt: 0.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Long Term Debt And Capital Lease Obligation: 32810000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Long Term Debt Payments: -7790000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Long Term Provisions: 4130000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Machinery Furniture Equipment: 36360000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Net Common Stock Issuance: 0.00
NURECA.NS cash_flow (annual, 2022-03-31) — Net Foreign Currency Exchange Gain Loss: -650000.00
NURECA.NS income_statement (annual, 2022-03-31) — Net Income: 449600000.00
NURECA.NS income_statement (annual, 2022-03-31) — Net Income Common Stockholders: 449600000.00
NURECA.NS income_statement (annual, 2022-03-31) — Net Income Continuous Operations: 449600000.00
NURECA.NS income_statement (annual, 2022-03-31) — Net Income From Continuing And Discontinued Operation: 449600000.00
NURECA.NS income_statement (annual, 2022-03-31) — Net Income From Continuing Operation Net Minority Interest: 449600000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Net Income From Continuing Operations: 609810000.00
NURECA.NS income_statement (annual, 2022-03-31) — Net Income Including Noncontrolling Interests: 449600000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Net Intangibles Purchase And Sale: -25950000.00
NURECA.NS income_statement (annual, 2022-03-31) — Net Interest Income: 44990000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Net Investment Purchase And Sale: -11310000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Net Issuance Payments Of Debt: -9220000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Net Long Term Debt Issuance: -7790000.00
NURECA.NS income_statement (annual, 2022-03-31) — Net Non Operating Interest Income Expense: 44990000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Net PPE: 77970000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Net PPE Purchase And Sale: -34040000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Net Short Term Debt Issuance: -1430000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Net Tangible Assets: 2003840000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Non Current Deferred Taxes Assets: 1010000.00
NURECA.NS income_statement (annual, 2022-03-31) — Normalized EBITDA: 630260000.00
NURECA.NS income_statement (annual, 2022-03-31) — Normalized Income: 450536344.11
NURECA.NS cash_flow (annual, 2022-03-31) — Operating Cash Flow: 13990000.00
NURECA.NS income_statement (annual, 2022-03-31) — Operating Income: 548050000.00
NURECA.NS income_statement (annual, 2022-03-31) — Operating Revenue: 2555480000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Ordinary Shares Number: 10000175.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Other Current Assets: 7110000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Other Current Liabilities: 20820000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Other Equity Interest: 1931980000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Other Intangible Assets: 28150000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Other Non Cash Items: -44990000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Other Non Current Liabilities: -10000.00
NURECA.NS income_statement (annual, 2022-03-31) — Other Non Operating Income Expenses: 2520000.00
NURECA.NS income_statement (annual, 2022-03-31) — Other Operating Expenses: 289610000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Other Payable: 11390000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Other Properties: 7250000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Other Receivables: 67400000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Other Short Term Investments: 844610000.00
NURECA.NS income_statement (annual, 2022-03-31) — Otherunder Preferred Stock Dividend: 0.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Payables: 79250000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Prepaid Assets: 151400000.00
NURECA.NS income_statement (annual, 2022-03-31) — Pretax Income: 609810000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Properties: 0.00
NURECA.NS cash_flow (annual, 2022-03-31) — Provisionand Write Offof Assets: 0.00
NURECA.NS cash_flow (annual, 2022-03-31) — Purchase Of Intangibles: -25950000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Purchase Of Investment: -355210000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Purchase Of PPE: -34040000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Raw Materials: 0.00
NURECA.NS income_statement (annual, 2022-03-31) — Reconciled Cost Of Revenue: 1326240000.00
NURECA.NS income_statement (annual, 2022-03-31) — Reconciled Depreciation: 14820000.00
NURECA.NS income_statement (annual, 2022-03-31) — Rent And Landing Fees: 6410000.00
NURECA.NS income_statement (annual, 2022-03-31) — Rent Expense Supplemental: 6410000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Repayment Of Debt: -7790000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Restricted Cash: 248210000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Retained Earnings: 957150000.00
NURECA.NS cash_flow (annual, 2022-03-31) — Sale Of Investment: 343900000.00
NURECA.NS income_statement (annual, 2022-03-31) — Selling And Marketing Expense: 219050000.00
NURECA.NS income_statement (annual, 2022-03-31) — Selling General And Administration: 271210000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Share Issued: 10000175.00
NURECA.NS income_statement (annual, 2022-03-31) — Special Income Charges: -7780000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Stockholders Equity: 2031990000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Tangible Book Value: 2003840000.00
NURECA.NS income_statement (annual, 2022-03-31) — Tax Effect Of Unusual Items: -333655.89
NURECA.NS income_statement (annual, 2022-03-31) — Tax Provision: 160210000.00
NURECA.NS income_statement (annual, 2022-03-31) — Tax Rate For Calcs: 0.26
NURECA.NS balance_sheet (annual, 2022-03-31) — Taxes Receivable: 0.00
NURECA.NS cash_flow (annual, 2022-03-31) — Taxes Refund Paid: -179510000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Total Assets: 2191300000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Total Capitalization: 2031990000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Total Debt: 44050000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Total Equity Gross Minority Interest: 2031990000.00
NURECA.NS income_statement (annual, 2022-03-31) — Total Expenses: 2007430000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Total Liabilities Net Minority Interest: 159310000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Total Non Current Assets: 129370000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Total Non Current Liabilities Net Minority Interest: 36930000.00
NURECA.NS income_statement (annual, 2022-03-31) — Total Other Finance Cost: 3050000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Total Tax Payable: 20580000.00
NURECA.NS income_statement (annual, 2022-03-31) — Total Unusual Items: -1270000.00
NURECA.NS income_statement (annual, 2022-03-31) — Total Unusual Items Excluding Goodwill: -1270000.00
NURECA.NS balance_sheet (annual, 2022-03-31) — Working Capital: 1939550000.00
NURECA.NS income_statement (annual, 2022-03-31) — Write Off: 7780000.00
NURECA.NS income_statement (annual, 2023-03-31) — +Operating Expense: 529340000.00
NURECA.NS income_statement (annual, 2023-03-31) — +Total Revenue: 1113230000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Accounts Payable: 49900000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Accounts Receivable: 42950000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Accumulated Depreciation: -27750000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Additional Paid In Capital: 987790000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Allowance For Doubtful Accounts Receivable: -250000.00
NURECA.NS income_statement (annual, 2023-03-31) — Amortization: 2930000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Available For Sale Securities: 72360000.00
NURECA.NS income_statement (annual, 2023-03-31) — Basic Average Shares: 10000175.00
NURECA.NS income_statement (annual, 2023-03-31) — Basic EPS: -8.25
NURECA.NS cash_flow (annual, 2023-03-31) — Beginning Cash Position: 82490000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Buildings And Improvements: 49150000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Capital Expenditure: -3960000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Capital Lease Obligations: 32450000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Capital Stock: 100000000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Cash And Cash Equivalents: 5040000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Cash Cash Equivalents And Short Term Investments: 1020620000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Cash Equivalents: 0.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Cash Financial: 5040000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Change In Inventory: 287000000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Change In Other Current Assets: 26140000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Change In Other Current Liabilities: -18800000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Change In Payable: 1770000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Change In Receivables: -13760000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Change In Working Capital: 285940000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Changes In Cash: -77360000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Common Stock: 100000000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Common Stock Equity: 1948810000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Construction In Progress: 0.00
NURECA.NS income_statement (annual, 2023-03-31) — Cost Of Revenue: 755310000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Current Assets: 1865630000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Current Capital Lease Obligation: 12180000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Current Debt: 820000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Current Debt And Capital Lease Obligation: 13000000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Current Liabilities: 88830000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Current Provisions: 2300000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Depreciation: 23880000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Depreciation And Amortization: 23880000.00
NURECA.NS income_statement (annual, 2023-03-31) — Depreciation And Amortization In Income Statement: 23880000.00
NURECA.NS income_statement (annual, 2023-03-31) — Depreciation Income Statement: 20950000.00
NURECA.NS income_statement (annual, 2023-03-31) — Diluted Average Shares: 10000175.00
NURECA.NS income_statement (annual, 2023-03-31) — Diluted EPS: -8.25
NURECA.NS income_statement (annual, 2023-03-31) — Diluted NI Availto Com Stockholders: -82500000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Dividends Payable: 130000.00
NURECA.NS income_statement (annual, 2023-03-31) — EBIT: -104060000.00
NURECA.NS income_statement (annual, 2023-03-31) — EBITDA: -80180000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Effect Of Exchange Rate Changes: -90000.00
NURECA.NS cash_flow (annual, 2023-03-31) — End Cash Position: 5040000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Financing Cash Flow: -15070000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Finished Goods: 327690000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Free Cash Flow: 98310000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Gain Loss On Investment Securities: -24440000.00
NURECA.NS income_statement (annual, 2023-03-31) — General And Administrative Expense: 34290000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Goodwill And Other Intangible Assets: 26130000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Gross Accounts Receivable: 43200000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Gross PPE: 88170000.00
NURECA.NS income_statement (annual, 2023-03-31) — Gross Profit: 357920000.00
NURECA.NS income_statement (annual, 2023-03-31) — Interest Expense: 3360000.00
NURECA.NS income_statement (annual, 2023-03-31) — Interest Expense Non Operating: 3360000.00
NURECA.NS income_statement (annual, 2023-03-31) — Interest Income: 42210000.00
NURECA.NS income_statement (annual, 2023-03-31) — Interest Income Non Operating: 42210000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Interest Paid Cff: -11870000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Interest Received Cfi: 12230000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Inventory: 344770000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Invested Capital: 1949630000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Investing Cash Flow: -164560000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Investmentin Financial Assets: 72360000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Issuance Of Debt: 60000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Long Term Capital Lease Obligation: 20270000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Long Term Debt: 0.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Long Term Debt And Capital Lease Obligation: 20270000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Long Term Debt Issuance: 0.00
NURECA.NS cash_flow (annual, 2023-03-31) — Long Term Debt Payments: 0.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Long Term Provisions: 7880000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Machinery Furniture Equipment: 39020000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Net Foreign Currency Exchange Gain Loss: -30000.00
NURECA.NS income_statement (annual, 2023-03-31) — Net Income: -82500000.00
NURECA.NS income_statement (annual, 2023-03-31) — Net Income Common Stockholders: -82500000.00
NURECA.NS income_statement (annual, 2023-03-31) — Net Income Continuous Operations: -82500000.00
NURECA.NS income_statement (annual, 2023-03-31) — Net Income From Continuing And Discontinued Operation: -82500000.00
NURECA.NS income_statement (annual, 2023-03-31) — Net Income From Continuing Operation Net Minority Interest: -82500000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Net Income From Continuing Operations: -107420000.00
NURECA.NS income_statement (annual, 2023-03-31) — Net Income Including Noncontrolling Interests: -82500000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Net Intangibles Purchase And Sale: 0.00
NURECA.NS income_statement (annual, 2023-03-31) — Net Interest Income: 37710000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Net Investment Purchase And Sale: -172830000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Net Issuance Payments Of Debt: 60000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Net Long Term Debt Issuance: 0.00
NURECA.NS income_statement (annual, 2023-03-31) — Net Non Operating Interest Income Expense: 37710000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Net PPE: 60420000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Net PPE Purchase And Sale: -3960000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Net Short Term Debt Issuance: 60000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Net Tangible Assets: 1922680000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Non Current Deferred Taxes Assets: 27290000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Non Current Prepaid Assets: 2790000.00
NURECA.NS income_statement (annual, 2023-03-31) — Normalized EBITDA: -102070000.00
NURECA.NS income_statement (annual, 2023-03-31) — Normalized Income: -99311813.44
NURECA.NS cash_flow (annual, 2023-03-31) — Operating Cash Flow: 102270000.00
NURECA.NS income_statement (annual, 2023-03-31) — Operating Income: -171420000.00
NURECA.NS income_statement (annual, 2023-03-31) — Operating Revenue: 1113230000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Ordinary Shares Number: 10000175.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Other Current Assets: 3350000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Other Current Liabilities: 10460000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Other Equity Interest: 1848820000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Other Intangible Assets: 26130000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Other Non Cash Items: -37690000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Other Non Current Assets: 80000.00
NURECA.NS income_statement (annual, 2023-03-31) — Other Non Operating Income Expenses: 2570000.00
NURECA.NS income_statement (annual, 2023-03-31) — Other Operating Expenses: 188750000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Other Payable: 8870000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Other Properties: 7960000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Other Receivables: 21590000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Other Short Term Investments: 1015580000.00
NURECA.NS income_statement (annual, 2023-03-31) — Otherunder Preferred Stock Dividend: 0.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Payables: 59580000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Prepaid Assets: 123770000.00
NURECA.NS income_statement (annual, 2023-03-31) — Pretax Income: -107420000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Properties: 0.00
NURECA.NS cash_flow (annual, 2023-03-31) — Provisionand Write Offof Assets: 3500000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Purchase Of Intangibles: 0.00
NURECA.NS cash_flow (annual, 2023-03-31) — Purchase Of Investment: -424810000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Purchase Of PPE: -3960000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Raw Materials: 17080000.00
NURECA.NS income_statement (annual, 2023-03-31) — Reconciled Cost Of Revenue: 755310000.00
NURECA.NS income_statement (annual, 2023-03-31) — Reconciled Depreciation: 23880000.00
NURECA.NS income_statement (annual, 2023-03-31) — Rent And Landing Fees: 10240000.00
NURECA.NS income_statement (annual, 2023-03-31) — Rent Expense Supplemental: 10240000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Repayment Of Debt: 0.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Restricted Cash: 299260000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Retained Earnings: 874060000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Sale Of Investment: 251980000.00
NURECA.NS income_statement (annual, 2023-03-31) — Selling And Marketing Expense: 111590000.00
NURECA.NS income_statement (annual, 2023-03-31) — Selling General And Administration: 145880000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Share Issued: 10000175.00
NURECA.NS cash_flow (annual, 2023-03-31) — Short Term Debt Issuance: 60000.00
NURECA.NS income_statement (annual, 2023-03-31) — Special Income Charges: -2550000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Stockholders Equity: 1948810000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Tangible Book Value: 1922680000.00
NURECA.NS income_statement (annual, 2023-03-31) — Tax Effect Of Unusual Items: 5078186.56
NURECA.NS income_statement (annual, 2023-03-31) — Tax Provision: -24920000.00
NURECA.NS income_statement (annual, 2023-03-31) — Tax Rate For Calcs: 0.23
NURECA.NS balance_sheet (annual, 2023-03-31) — Taxes Receivable: 9320000.00
NURECA.NS cash_flow (annual, 2023-03-31) — Taxes Refund Paid: -41470000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Total Assets: 2065790000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Total Capitalization: 1948810000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Total Debt: 33270000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Total Equity Gross Minority Interest: 1948810000.00
NURECA.NS income_statement (annual, 2023-03-31) — Total Expenses: 1284650000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Total Liabilities Net Minority Interest: 116980000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Total Non Current Assets: 200160000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Total Non Current Liabilities Net Minority Interest: 28150000.00
NURECA.NS income_statement (annual, 2023-03-31) — Total Other Finance Cost: 1140000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Total Tax Payable: 680000.00
NURECA.NS income_statement (annual, 2023-03-31) — Total Unusual Items: 21890000.00
NURECA.NS income_statement (annual, 2023-03-31) — Total Unusual Items Excluding Goodwill: 21890000.00
NURECA.NS balance_sheet (annual, 2023-03-31) — Working Capital: 1776800000.00
NURECA.NS income_statement (annual, 2023-03-31) — Write Off: 2550000.00
NURECA.NS income_statement (annual, 2024-03-31) — +Operating Expense: 434370000.00
NURECA.NS income_statement (annual, 2024-03-31) — +Total Revenue: 919280000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 51740000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 16150000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -23930000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 987790000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: 0.00
NURECA.NS income_statement (annual, 2024-03-31) — Amortization: 3160000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 3160000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 2920000.00
NURECA.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 10000175.00
NURECA.NS income_statement (annual, 2024-03-31) — Basic EPS: -1.79
NURECA.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 5040000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 24880000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -10860000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 20320000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 100000000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 140620000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 1438930000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 127500000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 13120000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Change In Inventory: 36260000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: -13450000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: 810000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Change In Payable: 1850000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Change In Receivables: 27050000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: 53430000.00
NURECA.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 135610000.00
NURECA.NS balance_sheet (annual, 2024-03-31) — Common Stock: 100000000.00